ALLURION TECHNOLOGIES INC Stock Price, News & Analysis

Allurion Technologies (NYSE:ALUR), a company focused on metabolically healthy weight loss, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 13, 2025.

Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a business update. Investors can access the call via phone using the numbers (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) with Conference ID 1905455. A webcast will be available in the Events section of Allurion's Investor Relations website.

Allurion Technologies (NYSE:ALUR) announced a strategic pivot focusing on low-dose GLP-1 combination therapy and muscle mass maintenance. The company has signed a term sheet with a strategic partner for expanding distribution and R&D, including potential development of a novel GLP-1 drug-eluting balloon.

Key developments include: submission of a protocol for a multi-center trial combining Allurion Program with low-dose GLP-1s, transition to distribution partners with GLP-1 prescription networks, and FDA acceptance of PMA application. Real-world data from 20,000 patients shows successful weight loss maintenance and muscle mass increases. Clinics piloting the combination approach grew 20% QoQ in Q2 2025.

Preliminary Q2 2025 results show $3 million revenue and $7 million operating loss, with operating expenses reduced by 50% YoY.

Allurion Technologies (NYSE: ALUR) has released new data demonstrating long-term effectiveness of the Allurion Program for weight loss. Two significant studies revealed impressive results:

The first study of 522 patients showed an average weight loss of 32 pounds (14.4kg) after four months, with 95% weight maintenance one year after balloon removal. The second study involving 497 patients demonstrated a 14.3% total body weight reduction, with 86% of patients maintaining weight loss after one year.

The company's AI-powered Virtual Care Suite supports sustainable weight loss through behavioral change, reinforcing Allurion's commitment to metabolically healthy weight loss solutions.

Allurion Technologies (NYSE:ALUR) has announced a strategic distribution partnership with Minogue Medical Inc. in Canada to advance metabolically healthy weight loss solutions. The partnership leverages Minogue Medical's 40-year experience and extensive network of dietitians, bariatric surgeons, and endoscopic specialists across Canada.

The collaboration aims to increase access to the Allurion Program combined with GLP-1 therapy, focusing on sustainable weight loss while maintaining muscle mass. Minogue Medical's established infrastructure and expertise in bariatric and obesity care will help implement Allurion's approach through a medically supervised, evidence-based framework.

Allurion Technologies (NYSE: ALUR) has announced the submission of its final Pre-Market Approval (PMA) module to the FDA, along with additional analyses from its AUDACITY Study for its weight loss balloon device. The pivotal study has successfully met both co-primary endpoints after new analyses.

The study involved 550 subjects randomized 1:1 between treatment and control groups. Using updated imputation methods, the treatment group showed a 4.34% mean difference in weight loss at 48 weeks with a 3.14% super-superiority margin (p = .0142), exceeding the pre-specified 3% margin. At 40 weeks, the difference was even more pronounced at 4.90% with a 3.75% margin (p = .0006).

Allurion Technologies (NYSE: ALUR) presented two significant studies at ASMBS 2025 Annual Meeting showcasing the effectiveness of their AI-powered weight loss program. The first study of 19,946 patients demonstrated a 12.4% average total body weight reduction at four months, with increased muscle mass (6.5%) and lean body mass (6%), while reducing fat mass by 11.3% and visceral fat by 12.3%. The second study tracked 223 patients over four years, showing sustained weight loss maintenance of 89%, with patients maintaining 10.1% total body weight reduction after four years compared to 11.4% at four months. The Allurion Program combines a procedure-less gastric balloon with AI-powered behavior change support, remote monitoring, and digital tools to achieve metabolically healthy weight loss without surgery or anesthesia.

Allurion Technologies (NYSE: ALUR), a company focused on metabolically healthy weight loss, announced that its Founder and CEO, Dr. Shantanu Gaur, will deliver a presentation at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4 at 3:45 p.m. ET. Interested parties can access the webcast through the Events & Presentations section of Allurion's investor relations website.

Allurion Technologies (NYSE: ALUR) presented significant clinical results at the SOFFCO.MM meeting in France, showcasing the effectiveness of their Allurion Program for weight loss. The study of 1,962 French patients demonstrated remarkable outcomes after four months:

- 12.2% average reduction in total body weight
- 6.6% increase in muscle mass percentage
- 11% decrease in fat mass
- 12.2% reduction in visceral fat index

Additionally, the company announced the resumption of shipments to France, with patient treatments expected to restart next month, marking their return to the French market with a focus on metabolically healthy weight loss.

Allurion Technologies (NYSE: ALUR) reported its Q1 2025 financial results, showing a revenue of $5.6 million, down from $9.4 million in Q1 2024. The company maintained its 2025 revenue guidance of $30 million while achieving significant cost reductions. Key highlights include: - Gross margin improved to 75% from 73% year-over-year - Operating expenses decreased by 37% to $11.4 million - Net operating loss reduced by 36% to $7.3 million - Cash balance of $20.4 million as of March 31, 2025 The company is progressing with its FDA approval process, having completed its Pre-PMA meeting and planning to submit the final PMA module by June. Allurion is also preparing to launch a trial combining its program with low-dose GLP-1 medications, aiming to maintain muscle mass and increase medication adherence.